Lisa Stirk
Overview
Explore the profile of Lisa Stirk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scholte M, Ramaekers B, Danopoulos E, Grimm S, Fernandez Coves A, Tian X, et al.
Pharmacoeconomics
. 2024 May;
42(8):829-832.
PMID: 38717708
No abstract available.
2.
Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, et al.
Pharmacoeconomics
. 2023 Sep;
41(11):1551.
PMID: 37665503
No abstract available.
3.
van Asselt A, Armstrong N, Kimman M, Peeters A, McDermott K, Stirk L, et al.
Pharmacoeconomics
. 2023 Feb;
41(3):239-251.
PMID: 36725788
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness...
4.
Wijnen B, Witlox W, Wolff R, Fayter D, Ramaekers B, Otten T, et al.
Pharmacoeconomics
. 2022 Oct;
41(1):33-42.
PMID: 36301414
Fenfluramine, tradename Fintepla, was appraised within the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process as Technology Appraisal 808. Within the STA process, the company...
5.
Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, et al.
Pharmacoeconomics
. 2022 Jul;
40(9):851-861.
PMID: 35802295
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (GlaxoSmithKline [GSK]) of Benlysta (belimumab) to submit evidence regarding...
6.
de Kock S, Stirk L, Ross J, Duffy S, Noake C, Misso K
Int J Technol Assess Health Care
. 2020 Dec;
37:e18.
PMID: 33280626
Objectives: To evaluate the methodological and reporting characteristics of search methods of systematic reviews (SRs) using the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA) checklist and the Risk Of...
7.
Witlox W, van Asselt A, Wolff R, Armstrong N, Worthy G, Chalker A, et al.
Pharmacoeconomics
. 2019 Dec;
38(4):317-324.
PMID: 31814080
As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZI) to submit evidence for the...
8.
Ryder S, Fox K, Rane P, Armstrong N, Wei C, Deshpande S, et al.
Pharmacoeconomics
. 2019 Apr;
37(7):895-919.
PMID: 30949988
Introduction: There is a lack of comprehensive cost information for cardiovascular events since 2013. Objective: A systematic review on the contemporary cost of cardiovascular events was therefore undertaken. Methods: Methods...
9.
Grimm S, Armstrong N, Ramaekers B, Pouwels X, Lang S, Petersohn S, et al.
Pharmacoeconomics
. 2018 Oct;
37(5):655-667.
PMID: 30293207
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo) to submit evidence of...
10.
Buyukkaramikli N, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, et al.
Pharmacoeconomics
. 2017 Nov;
36(2):145-159.
PMID: 29086363
The National Institute for Health and Care Excellence (NICE), as part of the institute's single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid, Celgene) to submit evidence...